Jae Park, MD
Hematology & Oncology · New York, NYNPI 1669593000
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $251,211 of the $315,573 with a category attached, or 79.6%. 21 manufacturers reported payments, led by Gilead at 40.8% of the total. Among hematology & oncology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 191 payments — averaging $1652.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$129K
- Amgen$62K
- Pfizer$25K
- Beigene, Ltd.$18K
- Jazz Pharmaceuticals Inc.$12K
- Autolus Inc$11K
- plus $59K from 15 others
Across 333 payments — averaging $27,003 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$6.7M
- Bristol Myers Squibb$753K
- Genentech, Inc.$705K
- Incyte Corporation$329K
- Gilead$312K
- Servier Bioinnovation$160K
- plus $58K from 3 others
What the payments were for
- Consulting fees$251,21180%
- Speaking & faculty fees$43,83914%
- Travel & lodging$17,4116%
- Food & beverage$3,1121%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead(2 entities) | 70 | $128,661 |
| Amgen | 35 | $62,151 |
| Pfizer | 7 | $24,692 |
| Beigene, Ltd. | 5 | $18,200 |
| Jazz Pharmaceuticals Inc. | 5 | $12,369 |
| Autolus Inc | 5 | $10,573 |
| Novartis | 8 | $9,530 |
| Servier Pharmaceuticals LLC | 9 | $8,168 |
| Sobi, Inc | 7 | $6,783 |
| E.r. Squibb & Sons, L.L.C. | 3 | $6,309 |
| Incyte Corporation | 10 | $4,718 |
| Novartis Pharma AG | 1 | $3,750 |
| AstraZeneca | 2 | $3,741 |
| Legend Biotech USA Inc. | 1 | $3,273 |
| Iovance Biotherapeutics, Inc. | 13 | $3,196 |
| Adaptive Biotechnologies Corporation | 5 | $3,031 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $3,000 |
| GSK | 1 | $2,226 |
| ADC Therapeutics America, Inc. | 1 | $700 |
| Servier Bioinnovation | 1 | $340 |
| Taiho Oncology, Inc. | 1 | $163 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$315,573 in reported general payments places this provider in the 95th percentile of 967 hematology & oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in New York
- Michael SchusterNew York$1.6M
- Charles SawyersNew York$1.6M
- Manuel Hidalgo-MedinaNew York$1.4M
- Ross LevineNew York$968K
- Joshua SabariNew York$761K
- Gail RobozNew York$738K
- Jeffrey LaurenceNew York$640K
- John AllanNew York$580K
- Ilan ShapiraNew York$475K
- John MascarenhasNew York$456K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.